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Objectives Our aim was to identify risk factors for coronary heart disease (CHD) events among asymptomatic persons with
low (130 mg/dl) low-density lipoprotein cholesterol (LDL-C).
Background Even among persons with low LDL-C, some will still experience CHD events and may benefit from more aggres-
sive pharmacologic and lifestyle therapies.
Methods The MESA (Multi-Ethnic Study of Atherosclerosis) is a prospective cohort of 6,814 participants free of clinical cardio-
vascular disease. Of 5,627 participants who were not receiving any baseline lipid-lowering therapies, 3,714 (66%) had
LDL-C 130 mg/dl and were included in the present study. Unadjusted and adjusted hazard ratios were calculated to
assess the association of traditional risk factors and biomarkers with CHD events. To determine if subclinical athero-
sclerosis markers provided additional information beyond traditional risk factors, coronary artery calcium (CAC) and
carotid intima media thickness were each separately added to the multivariable model.
Results During a median follow-up of 5.4 years, 120 (3.2%) CHD events were observed. In unadjusted analysis, age, male sex,
hypertension, diabetes mellitus, low high-density lipoprotein cholesterol (HDL-C), high triglycerides, and subclinical
atherosclerosis markers (CAC 0; carotid intima media thickness 1 mm) predicted CHD events. Independent pre-
dictors of CHD events included age, male sex, hypertension, diabetes, and low HDL-C. After accounting for all tradi-
tional risk factors, the predictive value of CAC was attenuated but remained highly significant. The relationship of all
independent clinical predictors remained robust even after accounting for elevated CAC.
Conclusions Among persons with low LDL-C, older age, male sex, hypertension, diabetes, and low HDL-C are associated with
adverse CHD events. Even after accounting for all such variables, the presence of CAC provided incremental
prognostic value. These results may serve as a basis for deciding which patients with low LDL-C may be consid-
ered for more aggressive therapies. (J Am Coll Cardiol 2011;58:364–74) © 2011 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.055Low values of low-density lipoprotein cholesterol (LDL-C)
are known to be associated with fewer adverse cardiovascular
events in both primary and secondary prevention studies
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July 19, 2011:364–74 Cardiac Events Among Persons With Low LDL-Cidentified lowering LDL-C as the primary target of
cholesterol-lowering therapy (1). In light of multiple trials
that have confirmed the benefit of aggressive cholesterol-
lowering therapy, the NCEP amended its guidelines in
2004 and suggested that for high-risk persons, the LDL-C
goal is 100 mg/dl, but when risk is very high, an LDL-C
goal of 70 mg/dl is a reasonable therapeutic strategy (2).
The results of these guidelines have helped to shape a new
paradigm shift in which some have argued that when it
comes to LDL-C, the lower the better.
To date, there is no known threshold LDL-C level below
which no further reduction in risk occurs. A study by
Lepper et al. (3) demonstrated that even among patients
with very low LDL-C (60 mg/dl), statin use was safe and
was associated with improved survival. The JUPITER (Justi-
fication for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin) study found that
among apparently healthy persons with LDL130 mg/dl and
igh-sensitivity C-reactive protein (hsCRP) 2 mg/l, treat-
ent with 20 mg of rosuvastatin significantly reduced the
ncidence of major cardiovascular events. It is estimated that if
hese so-called JUPITER criteria are applied to the U.S.
opulation, 11 million new persons may be candidates for
tatin therapy (4). Given the overall low event rate of most
rimary prevention trials, many patients need to be treated to
revent 1 cardiovascular event. Thus, identifying further risk
arkers for cardiovascular events may allow a more precise
dentification of persons who will benefit from statin therapy.
Given that even among patients with low LDL-C some will
till experience cardiovascular events, we sought to identify risk
actors for coronary heart disease (CHD) among patients with
o known coronary artery disease (CAD) and low LDL-C.
e hypothesized that both traditional risk factors (i.e., clinical
isk factors, inflammatory biomarkers, lipids) and imaging
iomarkers of pre-clinical atherosclerosis will predict CHD
vents. Our secondary aim was, thus, to identify the incremen-
al value of these imaging markers to the more traditional,
idely available clinical risk factors.
ethods
tudy participants. Details of the design and organization
f the MESA trial have been reported previously (5–7).
etween July 2000 and September 2002, 6,814 persons were
elected to be members of the MESA cohort at 6 field
enters (Baltimore, Maryland; Chicago, Illinois; Forsyth
ounty, North Carolina; Los Angeles, California; New
ork, New York; and St. Paul, Minnesota). The partici-
ants were required to be between 45 and 84 years of age
nd to have no clinical cardiovascular disease at the time of
nrollment in the study. The participants were recruited at
ach site from lists of residents, dwellings, and telephone
ompany customers. In the last few months of the recruit-
ent period, participants were also recruited from lists of
edicare beneficiaries obtained from the Centers for Medi-
are and Medicaid Services and by referrals from other
articipants, to ensure the enrollment of adequate numbersf elderly participants and partic-
pants from all 4 ethnic groups.
articipants identified them-
elves as white, black, Hispanic,
r Chinese at the time of enroll-
ent. The study was approved
y the institutional review boards
f each site, and all participants
ave written informed consent.
For the purposes of the pres-
nt study, 2,201 participants
32%) with LDL-C 130 mg/dl
ere excluded. Of the remaining
,613 participants, 899 (19%)
ho were on lipid-lowering ther-
pies at baseline were excluded.
he resulting population thus
onsisted of 3,714 subjects with
ow LDL-C who were free of
ardiovascular disease and were
ot receiving any lipid-lowering
herapies (Fig. 1). Among this
roup, 1,511 (41%) participants
ad LDL-C 100 mg/dl and
he remaining 2,203 (59%) had
DL-C between 101 and 130
g/dl.
omputed tomography scan-
ing. Carr et al. (8) have reported details of the methods
sed by the MESA trial for computed tomography (CT)
canning and for interpretation of the scans. Each of the 6
ESA centers assessed the amount of coronary artery
alcium (CAC) with the use of either an electron-beam CT
canner (at the Chicago, Los Angeles, and New York
enters) or a multidetector CT system (at the Baltimore,
Figure 1 Flowchart Illustrating Study Population
CHD  coronary heart disease; LDL-C  low-density lipoprotein cholesterol;
MESA  Multi-Ethnic Study of Atherosclerosis.
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CAD  coronary artery
disease
CHD  coronary heart
disease
CI  confidence interval
CIMT  carotid intima
media thickness
CT  computed
tomography
HDL-C  high-density
lipoprotein cholesterol
HR  hazard ratio
hsCRP  high-sensitivity
C-reactive protein
IMT  intima media
thickness
LDL-C  low-density
lipoprotein cholesterol
NCEP  National
Cholesterol Education
Program
ROC  receiver-operating
characteristic
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Cardiac Events Among Persons With Low LDL-C July 19, 2011:364–74Forsyth County, and St. Paul centers). Certified technolo-
gists placed radiographic phantoms containing identical and
known concentrations of calcium beneath the thorax of each
participant and then scanned the participant 2 times.
A radiologist or cardiologist read all CT scans at a single
center (the Los Angeles Biomedical Research Institute at
Harbor–University of California Los Angeles Medical Cen-
ter, Torrance, California) and used an interactive scoring
system similar to that of Yaghoubi et al. (9). The reader–
work station interface calibrated each tomographic image
according to the estimated attenuation of the calcium
phantom and then identified and quantified the CAC in
each image. The coronary calcium score (Agatston score)
(10) was calculated for each scan, and the mean of the 2
scans was used in all analyses. Intraobserver and interob-
server agreement was excellent (kappa statistics 0.93 and
0.90, respectively).
Carotid intima media thickness. Trained technicians in
each center performed B-mode ultrasonography of the right
and left near and far walls of the internal carotid and
common carotid arteries (11). Images were recorded using
the Logiq 700 ultrasound device (General Electric Medical
Systems, Waukesha, Wisconsin). An ultrasound reading
center (Department of Radiology, Tufts Medical Center,
Boston, Massachusetts) measured maximal carotid intima
media thickness (CIMT) of the internal and common
carotid sites as the mean of the maximum intima media
thickness (IMT) of the near and far walls of the right and
left sides.
Risk factors. As part of the baseline examination, clinical
eams at each of the 6 centers collected information on
ardiovascular risk factors, including family history, history
f smoking, hypertension, and diabetes mellitus. Using a
inamap Pro 1000 automated oscillometric sphygmoma-
ometer (Critikon), resting blood pressure was measured 3
imes with the participant in the seated position. A central
aboratory (University of Vermont, Burlington, Vermont)
easured levels of total and high-density lipoprotein cho-
esterol (HDL-C), triglycerides, plasma glucose, and
sCRP in blood samples obtained after a 12-h fast.
Diabetes was defined as a fasting plasma glucose level
125 mg/dl or a history of medical treatment for diabetes.
he body mass index was calculated as the weight in
ilograms divided by the square of the height in meters.
amily history of CHD was obtained by asking the partic-
pants whether any member of their immediate family
parents, siblings, and children) had had a fatal or nonfatal
yocardial infarction, coronary angioplasty, or coronary
rtery bypass graft surgery. The participants were classified
s current cigarette smokers, former smokers, or persons
ho had never smoked.
ollow-up. New cardiovascular events were recorded for a
edian of 5.4 years. At intervals of 9 to 12 months, an
nterviewer contacted each participant or a family member
y telephone to inquire about interim hospital admissions,
utpatient diagnoses of cardiovascular disease, and deaths.To verify self-reported diagnoses, medical records were
reviewed for participants who had been hospitalized or
received an outpatient diagnosis of cardiovascular disease.
Records were obtained for 98% of reported cardiovascular
events associated with hospitalization. For participants who
had died of cardiovascular causes outside the hospital,
interviews were conducted with the next of kin and copies of
death certificates were requested.
Trained personnel abstracted data from medical records
that reported possible cardiovascular events. Two physicians
who were members of the MESA trial mortality and
morbidity review committee independently classified events
and assigned incidence dates. If they disagreed, the full
committee made the final classification.
Coronary heart disease events consisted of myocardial
infarction, angina, resuscitated cardiac arrest, or CHD
death. The diagnosis of myocardial infarction was based on
a combination of symptoms, electrocardiographic findings,
and levels of cardiac biomarkers. Hospital records and
family interviews were used to determine whether deaths
were related to CHD. A death was considered related to
CHD if it occurred within 28 days after a myocardial
infarction, if the participant had chest pain within the 72 h
before death, or if the patient had a history of CHD and
there was no known nonatherosclerotic, noncardiac cause of
death.
The adjudicators graded angina as definite, probable, or
absent on the basis of their clinical judgment. A classifica-
tion of definite or probable angina required clear and
definite documentation of symptoms distinct from the
diagnosis of myocardial infarction. A classification of defi-
nite angina also required objective evidence of reversible
myocardial ischemia or obstructive CAD. A more detailed
description of the MESA trial follow-up methods is avail-
able online (12).
Statistical analysis. We used chi-square tests for categor-
ical variables and 1-way analysis of variance tests for
continuous variables to assess for differences among partic-
ipants with and without CHD events. Medians of
C-reactive protein were compared using the Kruskal-Wallis
equality of populations rank test.
We used unadjusted and adjusted Cox proportional
hazards regression analyses to estimate hazard ratio (HR)
for CHD events. The CAC score was examined as a binary
score (presence or absence of any CAC) and as a categorical
variable (0, 1 to 100, 101 to 400, and 400). CIMT was
examined across a binary cutpoint (with 1 mm considered
elevated) as well as across increasing quartiles of CIMT
thickness. Low HDL-C was defined as 40 mg/dl for men
and 50 mg/dl for women. Elevated triglycerides were
considered 150 mg/dl.
All risk factors that have an established association with
CHD events were included in the multivariable model. To
isolate the effect of adding imaging markers (CAC and
CIMT) to clinical and biomarker data, which are more
readily available to clinicians, the multivariable model was
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July 19, 2011:364–74 Cardiac Events Among Persons With Low LDL-Cinitially computed without any imaging markers. We then
separately added CAC (both as binary and categorical
variable) and CIMT to the multivariable model to deter-
mine the incremental predictive value of these markers. In
addition, CAC and CIMT were also added to a multivari-
able model that included the Framingham risk score (as a
continuous variable). We compared the area under the
receiver-operating characteristic (ROC) curve to identify
the incremental value of adding CAC to a multivariable
model that includes nonimaging clinical characteristics as
well as to the Framingham risk score.
To describe the frequency of coronary events according to
time, we constructed Nelson-Aalen cumulative hazard ra-
tios curves for CHD events among participants with
LDL-C 130 mg/dl. The data were stratified according to
the presence or absence of CAC score. All analyses were
performed with Stata software version 11.0 (StataCorp,
College Station, Texas). Two-tailed p values 0.05 were
considered significant.
Results
Baseline characteristics. The final study population con-
sisted of 3,714 participants (age 62  11 years, 48% males).
able 1 shows the baseline characteristics of the entire study
opulation.
HD events. During the mean follow-up of 5.4 years
Baseline Characteristics of Study ParticipantsTable 1 Baseline Characteristics of Study Participants
Variable Total Population
n 3,714
Age, yrs 61.6 10.5
Sex, % male 47.9
Race, %
Caucasian 36.9
Chinese 13.0
African American 28.5
Hispanic 21.7
Cigarette smoking, %
Never 49.5
Former 36.6
Current 13.9
Hypertension, % 42.5
Diabetes mellitus, % 12.8
Total cholesterol, mg/dl 178.5.8 24.6
HDL, mg/dl 51.9 16.1
LDL, mg/dl 102.4 19.8
TG, mg/dl 103 (72–154)
Non-HDL, mg/dl 126.6 23.8
CRP, mg/l 1.87 (0.79–4.31)
IMT 1 mm, % 31.1
CAC score 0, % 44.4
Framingham risk score 7.45
Values are n, mean  SD, %, or median (interquartile range).
CAC coronary artery calcium; CRP C-reactive protein; HDL high-density lipoprotein; IMT
ntima media thickness; IQR  interquartile range; LDL  low-density lipoprotein; TG 
riglycerides.range 0 to 7 years), 120 (3.2%) subjects experienced CHDevents, corresponding to 5.9 CHD events per 1,000 person-
years of follow-up. Table 2 shows the baseline characteris-
tics of the study population stratified by participants who
had and did not have CHD events. Participants experienc-
ing CHD events were more likely to be older males with
diabetes and hypertension and to have higher levels of
triglycerides but lower HDL-C. Correspondingly, they
were found to have a significantly higher Framingham risk
score (13.9% vs. 7.2% risk of a hard CHD event over the
next decade, p  0.001). Participants experiencing CHD
events during the follow-up period had a higher baseline
prevalence of CAC as well a higher baseline CIMT. There
was no difference in the CHD event rate for participants
with LDL-C 100 mg/dl versus those with LDL-C
between 101 and 130 mg/dl (Fig. 2). Figure 3 illustrates the
relationship of CAC and CIMT with CHD events. There
was a stepwise increase in events rates across increasing
categories of CAC. Conversely, there was a less pronounced
relationship between CHD events across increasing quar-
tiles of CIMT.
Unadjusted predictors of CHD events. Among the 3,714
participants with LDL-C 130 mg/dl, significant predic-
tors of CHD events included older age, male sex, diabetes,
hypertension, low HDL-C, and elevated triglycerides (Table 3).
However, family history of myocardial infarction, tobacco
use, and elevated hsCRP were not associated with an
increased risk.
Of the imaging markers evaluated, the presence of any
CAC was the most powerful predictor of events (HR: 13.5)
Baseline Characteristics Stratified byOccurrence of CHD Events During Follow-UpTable 2 B seline Characteristics Stratified byOccurrence of CHD Events During Follow-Up
Variable No CHD CHD p Value
Age, yrs 61.3 69.1 0.001
Sex, % male 46.9 75.0 0.001
Total cholesterol, mg/dl 178.6 176.1 0.27
Non-HDL cholesterol, mg/dl 126.4 131.0 0.04
HDL cholesterol, mg/dl 52.2 45.1 0.001
LDL cholesterol, mg/dl 102.3 103.0 0.70
Triglycerides, mg/dl, median 102.0 125.5 0.002
Race, % 0.39
Caucasian 36.6 43.3
Chinese 13.1 9.2
African American 28.6 27.5
Hispanic 21.7 20.0
Hypertension, % 41.5 70.8 0.001
Diabetes mellitus, % 12.3 29.2 0.001
Cigarette smoking, % 0.15
Never 49.8 42.5
Former 36.3 45.0
Current 14.0 12.5
CRP, mg/l, median 1.89 1.66 0.85*
CAC 0, % 42.9 89.2 0.001
Carotid IMT 1 mm, % 30.4 53.1 0.001
Framingham risk score 7.2 13.9 0.001*By Kruskal-Wallis.
CHD  coronary heart disease; other abbreviations as in Table 1.
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Cardiac Events Among Persons With Low LDL-C July 19, 2011:364–74and demonstrated a step-wise increased level of risk across
categories of increasing CAC scores. Increased CIMT was
also found to have a significant unadjusted association with
CHD events.
Multivariable-adjusted predictors. In the initial multi-
variable model (Table 3) consisting of traditional risk factors
only, advanced age, male sex, hypertension, diabetes, and
low HDL-C levels emerged as independent predictors of
CHD events among participants with LDL-C130 mg/dl.
Figure 2 Cumulative Incidence of CHD Events According to Ba
The incidence of CHD is compared over time by baseline LDL-C. There was no diff
versus those with LDL-C between 101 and 130 mg/dl (red line). Abbreviations as
Figure 3 CHD Outcomes Across CAC and Carotid IMT
The rates of incident coronary heart disease (CHD) per 1,000 person-years at risk
intima media thickness (IMT). There was a substantial stepwise increase in event
between CHD events across increasing quartiles of carotid IMT.hen CAC was added to the multivariable model, all other
ndependent clinical predictors remained robust; however,
he presence of CAC provided significant incremental value
or predicting CHD events (HR: 4.23; 95% confidence
nterval [CI]: 2.28 to 7.86). Furthermore, there was a
tepwise increase in risk across escalating categories of
igher CAC scores, with HRs of 2.67 (95% CI: 1.32 to
.39), 5.84 (95% CI: 2.88 to 11.85), and 9.29 (95% CI: 4.49
o 19.2) for CAC 1 to 100, 101 to 400, and 400,
LDL-C Levels
in event rate for participants with LDL-C 100 mg/dl (blue line)
ure 1.
splayed by increasing categories of coronary artery calcium (CAC) and carotid
across increasing categories of CAC, but a less pronounced relationshipseline
erence
in Figare di
rates
m grou
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July 19, 2011:364–74 Cardiac Events Among Persons With Low LDL-Crespectively. Similar HRs were obtained when CAC was
added to a multivariable model that included the Framing-
ham risk score (HR: 4.13, 95% CI: 2.05 to 8.35; HR: 9.66,
95% CI: 4.81 to 19.40; and HR: 16.98, 95% CI: 8.36 to
34.49) for CAC 1 to 100, 101 to 400, and 400,
respectively.
When adding CAC to the multivariable model that
included all traditional risk factors, the area under the ROC
curve increased from 0.815 to 0.857 (p  0.001). When
CAC was added to the Framingham risk score, the area
under the ROC curve increased from 0.756 to 0.829 (p 
0.001) (Online Fig. 1).
Conversely, when increased CIMT (1 mm) was intro-
duced to the multivariable model that consisted of all
traditional risk factors, its association was no longer signif-
icant (HR: 1.42, 95% CI: 0.93 to 2.18). Similar lack of
statistical significance of CIMT in our multivariable model
was observed across increasing quartiles of CIMT (HR:
0.79, 95% CI: 0.38 to 1.62; HR: 0.97, 95% CI: 0.50 to 1.88;
and HR: 1.30, 95% CI: 0.71 to 2.36 for the second, third,
and fourth quartiles, respectively, when the lowest quartile
Unadjusted and Adjusted Hazard Ratios for CHD EventsTable 3 Unadjusted and Adjusted Hazard Ratios for CHD Event
Variable Unadjusted
Age, 10 yrs 2.12 (1.76–2.55)
Male 3.37 (2.23–5.10)
Race
Caucasian (Reference)
Chinese 0.61 (0.32–1.17)
African American 0.86 (0.56–1.33)
Hispanic 0.83 (0.51–1.35)
Hypertension 3.46 (2.32–5.09)
Diabetes mellitus 3.01 (2.03–4.46)
Family history of MI 1.39 (0.95–2.04)
Low HDL-C 2.47 (1.72–3.55)
High TG 1.93 (1.34–2.78)
hsCRP 2 mg/l 0.91 (0.64–1.31)
Cigarette smoking
Never (Reference)
Former 1.44 (0.98–2.11)
Current 1.06 (0.60–1.88)
Framingham risk score, 1% increase 1.10 (1.08–1.12)
CIMT 1 mm 2.63 (1.82–3.81)
CIMT quartiles
1 (Reference)
2 1.27 (0.66–2.43)
3 1.39 (0.73–2.63)
4 3.44 (1.97–6.02)
CAC score 0 10.92 (6.14–19.42)
0 (Reference)
1–100 5.13 (2.66–9.91)
101–400 13.08 (6.92–24.72)
400 26.66 (14.35–49.53)
Values are hazard ratios (95% confidence interval). *Multivariable model using carotid intima medi
CIMT 1 mm, and 4 calcium groups. ‡Multivariable model using 4 quartiles of CIMT and 4 calciu
hsCRP  high-sensitivity C-reactive protein; other abbreviations as in Tables 1 and 2.was used as the reference group) or if continuous IMT (perstandard deviation increase) was used to represent this risk
factor in the model (HR: 1.10, 95% CI: 0.94 to 1.30).
In the final multivariable model consisting of all tradi-
tional risk factors as well as CAC and CIMT, the presence
of any CAC was associated with a fourfold increased risk of
CHD events; the respective risk was 9-fold higher among
subjects with CAC400. In this same model, hypertension
and low HDL-C were the strongest nonimaging clinical
risk predictors and were each associated with an approxi-
mately 2-fold higher risk of CHD events (Table 3).
CHD outcomes combining multiple risk factors. Among
participants with LDL-C 130 mg/dl, aside from age and
sex, the 3 independent clinical predictors that emerged as
significant risk factors were hypertension, diabetes, and low
HDL-C. Figure 4 demonstrates the unadjusted cumulative
event curves for CHD events according to increasing
number of these 3 risk factors. The differences among these
curves were statistically significant (p  0.001). In age- and
sex-adjusted analysis, as compared with subjects having no
underlying diabetes mellitus, hypertension, or low HDL-C
(36%), the HRs for CHD events for subjects with 1 risk
djusted for Traditional Risk Factors
Adjusted for All Risk Factors
(CAC  CIMT Included)*
1.88 (1.51–2.34) 1.26 (1.00–1.62)
2.88 (1.82–4.56) 1.77 (1.09–2.87)
(Reference) (Reference)
0.72 (0.36–1.43) 0.88 (0.44–1.77)
0.70 (0.42–1.17) 0.97 (0.57–1.66)
0.70 (0.41–1.19) 0.91 (0.52–1.57)
2.30 (1.47–3.59) 2.13 (1.34–3.38)
1.64 (1.05–2.58) 1.37 (0.86–2.20)
1.30 (0.87–1.93) 1.10 (0.73–1.66)
2.44 (1.59–3.74) 2.29 (1.47–3.56)
1.31 (0.85–2.02) 1.17 (0.75–1.85)
0.94 (0.63–1.41) 0.86 (0.57–1.31)
(Reference) (Reference)
1.15 (0.75–1.76) 1.13 (0.73–1.76)
1.40 (0.75–2.63) 1.22 (0.65–2.32)
— 1.04 (1.02–1.07)†
— 1.05 (0.68–1.62)
—
— (Reference)‡
— 0.79 (0.38–1.63)
— 0.96 (0.49–1.86)
— 0.94 (0.51–1.72)
— 4.12 (2.20–7.71)§
— (Reference)
— 2.75 (1.36–5.56)
— 5.82 (2.84–11.93)
— 9.05 (4.27–19.20)
ess (CIMT)1 mm and 4 calcium groups. †Multivariable model including Framingham risk score,
ps. §Multivariable model using CIMT 1 mm and CAC 0.s
A
a thicknfactor (42%), 2 risk factors (18%), and all 3 risk factors (4%)
o
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Cardiac Events Among Persons With Low LDL-C July 19, 2011:364–74were 2.79 (95% CI: 1.47 to 5.36), 5.15 (95% CI: 2.70 to
9.84) and 9.97 (95% CI: 4.84 to 20.54), respectively. This
relationship persisted even after adjusting for increased
categories of CAC (HRs: 2.39, 4.14, and 6.80, respectively,
for subjects with 1, 2, or 3 risk factors).
In addition, we evaluated how the presence of CAC
modifies the risk profile offered by each of these predictors.
Figure 5 shows the cumulative time to event curves for each
f these risk factors stratified by the presence or absence of
AC. For each independent predictor, the presence of
AC was found to be associated with higher events. To
nalyze the additive effect of multiple risk factors and how
he presence or absence of CAC may modify this risk,
igure 6 shows the cumulative time to event curves across
escalating number of risk factors. Regardless of the number
of risk factors present, the presence of CAC was found to
consistently be associated with higher CHD events.
Discussion
Our study shows that, among persons with no known CAD
and low LDL-C, clinical and imaging risk markers can be
used to identify patients who have increased risk of having
CHD events develop. In such populations, male sex, older
age, hypertension, low HDL-C, and diabetes can each be
used to identify persons who have a higher risk of future
events. When considered collectively, the presence of mul-
tiple such risk factors can be used to identify the group that
is most likely to experience future events. However, our
study also shows that even after accounting for all relevant
traditional clinical risk factors (and even after considering
populations with multiple coexisting risk factors), the pres-
Figure 4 Cumulative Incidence of CHD Events Across Increase
The incidence of CHD over time is compared by number of baseline risk factors am
Risk factors include hypertension, diabetes mellitus, and low high-density lipoproteence and burden of CAC can be used to further enhancerisk assessment, whereas its absence is associated with a very
low event rate.
There are several important reasons to study popula-
tions with low LDL-C. First, although many of the risk
factors identified in our study (i.e., hypertension, low
HDL-C) have been extensively studied, the relevance of
these risk factors among persons with baseline low
LDL-C is less established. When considering a group of
patients with no known CAD and low LDL-C, it is thus
important to demonstrate that previously recognized risk
factors (which were validated in more heterogeneous
populations) remain significant. For instance, deGoma et
al. (13) showed that, among persons with low LDL-C,
low HDL-C is still associated with increased risk. How-
ever, many persons in their study had known ischemic
heart disease and more than half of them were receiving
lipid-lowering therapies. A recent analysis from the
JUPITER study (14) suggests that, among patients
treated with potent statin therapy, low HDL-C is not
predictive of residual cardiovascular risk. However, when
examining the patients who were randomly assigned to
the placebo group (i.e., patients not on lipid-lowering
therapies, and therefore very similar to the patients
included in our study), low HDL-C was associated with
a substantially elevated risk. Another important reason to
specifically study populations with low LDL-C is to
examine whether imaging risk factors have any additional
predictive value after considering all traditional risk
factors and nonimaging biomarkers that are typically
available to clinicians. Conversely, it is also important to
examine whether the predictive power of such risk factors
persists after accounting for imaging biomarkers such as
ber of Risk Factors Among Persons With Low LDL-C
ersons with low (130 mg/dl) LDL-C.
lesterol. Abbreviations as in Figure 1.d Num
ong p
in choCIMT and CAC.
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tients to achieve LDL 100 mg/dl is reserved for patients
at very high risk, recent trends have shown that clinicians
are now using high doses of statins (15) even for patients
who may already be at NCEP goal levels. While such
practice patterns are based on intuition rather than evidence,
we do know that even among patients with very low LDL,
there remains a subgroup of patients who experience car-
diovascular events. Thus, risk stratification beyond LDL-C
Figure 5 Cumulative Incidence of CHD Events Among Participa
Across Risk Factors and Stratified by Presence or Ab
The incidence of CHD over time is compared among participants with and without
each graph, separate cumulative incidence curves are displayed for participants w
(blue lines). Next to each curve, the total number of events as well as the numbe
ent or absent—the presence of CAC provides incremental prognostic value. Abbremay be important in more accurately identifying CHD risk.Whereas numerous studies have sought to identify and
assess different methods of risk stratification that would add
value beyond that of LDL-C levels, far less is known about
whether it is possible to distinguish high-risk from low-risk
patients from among patients who already have very low
LDL-C levels. Indeed, the identification of such patients
may help to identify a subgroup of patients who would be
appropriate candidates for more aggressive therapies.
Our findings support the need for comprehensive risk
ith Low LDL-C (<130 mg/dl)
of CAC
gh-density lipoprotein (HDL) cholesterol, diabetes mellitus, and hypertension. For
onary artery calcifications (CAC [CAC 0]) (red lines) and without CAC (CAC  0)
-risk persons is displayed. For each individual risk factor—and regardless if pres-
s as in Figure 1.nts W
sence
low hi
ith cor
r of at
viationassessment in patients with low LDL-C. Specifically, low
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Cardiac Events Among Persons With Low LDL-C July 19, 2011:364–74HDL-C and the presence of hypertension or diabetes
should alert clinicians of patients who might benefit from
preventive measures. While systematic screening for CAC
cannot be suggested on the basis of our findings (and such
a strategy is also unlikely to be a cost-effective strategy), for
selected persons, those for whom such information would
result in a change in medical therapy, assessing for CAC
may be a reasonable approach. In such patients, the presence
of CAC would translate into a higher risk profile and could
thus be used to initiate or intensify medical management.
Conversely, the absence of coronary calcification can be used
as a reassurance and may signal that there is no need to
intensify current therapies, or the threshold for LDL-C–
lowering therapy can be higher than if there was advanced
subclinical atherosclerosis. In particular, middle-aged per-
sons who have 2 or fewer risk factors and no coronary
calcification (Fig. 6) have an extremely low event rate over a
Figure 6 Cumulative Incidence of CHD Events Among Participant
Across an Increasing Number of Risk Factors and S
The incidence of CHD over time is compared among participants with increasing n
density lipoprotein cholesterol. For each graph, separate cumulative incidence cur
(red lines) and without CAC (CAC  0) (blue lines). Next to each curve, the total n
or absence of CAC provides incremental prognostic value across increased numbe6-year follow-up.Recently, the JUPITER study demonstrated that, among
persons with LDL 130 mg/dl and hsCRP 2 mg/l,
treatment with 20 mg of rosuvastatin significantly reduced
the incidence of major cardiovascular events, whereas in our
study, hsCRP was not found to be a predictor of future
events. It is thought that JUPITER participants represent
adults who are more likely to benefit from statin therapy;
however, since no “control group” of individuals with low
hsCRP was included in that study, it is unclear whether
patients with low hsCRP who would have otherwise met
criteria for inclusion in the JUPITER study would have also
benefited from the pharmacological intervention studied. A
recent population study from the ARIC (Atherosclerosis
Risk in Communities) study has shown that JUPITER
eligible patients with a hsCRP 2 mg/l have a higher event
rate than those who have a lower CRP (16), but other
studies did not identify any relationship between hsCRP
h Low LDL-C (<130 mg/dl)
fied by Presence or Absence of CAC
s of the following risk factors: hypertension, diabetes mellitus, and low high-
displayed for participants with coronary artery calcifications (CAC [CAC 0])
r of events as well as the number of at-risk persons is displayed. The presence
raditional risk factors. Abbreviations as in Figure 1.s Wit
trati
umber
ves are
umbe
rs of tand cardiovascular risk (17–19).
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imaging for pre-clinical atherosclerosis. Although we found
CAC to be a powerful predictor among persons with low
LDL-C, the association of CIMT with events was weaker.
Nevertheless, there are convincing data supporting the
independent prognostic value of CIMT, and, therefore, the
reason for the attenuated relationship observed in our study
is not entirely clear.
Although our study identifies CAC as a powerful risk
marker, the potential benefits of CAC scanning need to be
weighed against the potential harmful effects of radiation.
The mean effective radiation dose of a CAC scan when
using appropriate protocols is 1 mSv (20). Although cau-
sality has not been firmly established, using this dose, the
estimated cancer risk of a single CAC scan of a patient at
age 55 years may be expected to result in a lifetime excess
risk of 3 and 8 cancers per 100,000 persons for men and
women, respectively (21).
Study limitations. In our study, patients and their physi-
ians were informed of their CAC score. This process might
ave caused patients with higher CAC to receive more
reventive therapies. However, in such cases, the effect of
AC on subsequent events would be attenuated. Our study
lso eliminated patients who were treated with lipid-
owering therapies at baseline. That may have introduced a
election bias because patients on lipid-lowering therapies
ere older and more likely to have other comorbidities such
s hypertension and diabetes. Consequently, patients ex-
luded for this reason also had a higher Framingham risk
core as well as an increased burden of pre-clinical
therosclerosis.
Our study is limited by a relatively low event rate, and it
s therefore possible that increased events over a longer
ollow-up of the MESA study cohort may identify addi-
ional risk factors over time. Finally, although our study can
e used to identify important associations with risk of CHD
vents, future prospective randomized trials will be required
o determine whether clinical outcomes can be improved by
etecting and treating such higher-risk persons.
onclusions
mong an ethnically diverse, middle-aged and older cohort
ith low LDL-C and no known baseline cardiovascular
isease, older age, male sex, hypertension, diabetes, and low
DL-C were associated with increased risk of subsequent
HD events. After accounting for all such variables and
ven among persons with multiple clinical risk factors, the
resence of CAC provided incremental prognostic value.
hile these results may serve as a basis for deciding which
atients with low LDL-C may be considered for more
ggressive therapies, future studies are needed to identify
hether selective treatment of particular subgroups of pa-
ients with low LDL-C would translate into improved
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